These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20968146)

  • 1. Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma.
    De Dosso S; Martin V; Zanellato E; Frattini M; Saletti P
    Tumori; 2010; 96(4):627-8. PubMed ID: 20968146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case.
    Phan LK; Hoff PM
    Dis Colon Rectum; 2007 Mar; 50(3):395-8. PubMed ID: 17252287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab in refractory squamous cell carcinoma of the anal canal.
    Rogers JE; Eng C
    J Gastrointest Cancer; 2014 Dec; 45 Suppl 1():198-200. PubMed ID: 24908401
    [No Abstract]   [Full Text] [Related]  

  • 4. EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience.
    Kim DW; Byer J; Kothari N; Mahipal A; Chang YD; Kim RD
    Oncology; 2017; 92(4):190-196. PubMed ID: 28152526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma.
    Rogers JE; Jácome AAA; Ohinata A; Wolff R; Morris VK; Johnson B; Mehdizadeh A; Rothschild ND; Ahmed SU; Guerra JL; Eng C
    Expert Rev Anticancer Ther; 2020 Oct; 20(10):901-908. PubMed ID: 32799569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma.
    Valery M; Cervantes B; Smolenschi C; Boilève A; Boige V; Malka D; Hollebecque A; Ducreux M
    Dig Liver Dis; 2023 Mar; 55(3):407-411. PubMed ID: 36088220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor inhibition induces trichomegaly.
    Dueland S; Sauer T; Lund-Johansen F; Ostenstad B; Tveit KM
    Acta Oncol; 2003; 42(4):345-6. PubMed ID: 12899508
    [No Abstract]   [Full Text] [Related]  

  • 8. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
    García-Foncillas J; Díaz-Rubio E
    Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
    Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
    Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma: experience from an area in which betel nut chewing is popular.
    Chang PM; Hsieh YY; Chen MH; Tzeng CH; Chu PY; Chang SY; Chen PM; Yang MH
    J Chin Med Assoc; 2010 Jun; 73(6):292-9. PubMed ID: 20603086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck.
    Burtness B
    J Clin Oncol; 2005 Aug; 23(24):5440-2. PubMed ID: 16009959
    [No Abstract]   [Full Text] [Related]  

  • 12. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).
    Tomblyn MB; Goldman BH; Thomas CR; Benedetti JK; Lenz HJ; Mehta V; Beeker T; Gold PJ; Abbruzzese JL; Blanke CD;
    J Thorac Oncol; 2012 May; 7(5):906-12. PubMed ID: 22481235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
    Khawandanah M; Baxley A; Pant S
    J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.
    Burtness B; Goldwasser MA; Flood W; Mattar B; Forastiere AA;
    J Clin Oncol; 2005 Dec; 23(34):8646-54. PubMed ID: 16314626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor inhibition in metastatic anal cancer.
    Rogers JE; Ohinata A; Silva NN; Mehdizadeh A; Eng C
    Anticancer Drugs; 2016 Sep; 27(8):804-8. PubMed ID: 27272412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
    Tahara M; Shirao K; Boku N; Yamaguchi K; Komatsu Y; Inaba Y; Arai T; Mizunuma N; Satoh T; Takiuchi H; Nishina T; Sakata Y
    Jpn J Clin Oncol; 2008 Nov; 38(11):762-9. PubMed ID: 18836202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases.
    Khater R; Frenay M; Bourry J; Milano G; Namer M
    Cancer Treat Rep; 1986 Nov; 70(11):1345-6. PubMed ID: 3768879
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
    Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
    J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
    Folprecht G; Lutz MP; Schöffski P; Seufferlein T; Nolting A; Pollert P; Köhne CH
    Ann Oncol; 2006 Mar; 17(3):450-6. PubMed ID: 16303861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.